Atrial Septal Defect Global Market Report 2024

An atrial septal defect (ASD) is a congenital heart defect characterized by an abnormal opening in the septum, the wall separating the heart's two upper chambers (atria). This opening allows oxygen-rich blood from the left atrium to mix with oxygen-poor blood in the right atrium, leading to increased blood flow to the lungs and potential complications such as pulmonary hypertension and heart failure over time.

The main treatment options for atrial septal defects include surgical closure, transcatheter closure, hybrid procedures, and medication therapy. Surgical closure involves repairing or sealing the abnormal opening through surgical intervention. Diagnostic techniques used for ASD include chest x-rays, electrocardiograms, cardiac catheterization, transesophageal echocardiography, and pulse oximetry. These diagnostics are facilitated by medical devices and pharmaceutical products and are utilized in pediatric and adult patients across various healthcare settings, including hospitals, ambulatory surgical centers, cardiac clinics, and others.

The arterial septal defect research report is one of a series of new reports that provides arterial septal defect market statistics, including the arterial septal defect industry's global market size, regional shares, competitors with an arterial septal defect market share, detailed arterial septal defect market segments, market trends and opportunities, and any further data you may need to thrive in the arterial septal defect industry. This arterial septal defect market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The atrial septal defect market size has grown strongly in recent years. It will grow from $3.85 billion in 2023 to $4.14 billion in 2024 at a compound annual growth rate (CAGR) of 7.7%. The growth observed in the historic period can be attributed to several factors. These include the rise in the number of congenital heart disease cases, increased funding for research and development of treatments for atrial septal defects (ASD), high awareness about congenital heart defects among parents and healthcare providers, higher rates of pediatric surgeries for ASD, approval of new ASD closure devices and therapies by regulatory bodies such as the FDA, and the expansion of healthcare facilities specializing in cardiac care.

The atrial septal defect market size is expected to see strong growth in the next few years. It will grow to $5.6 billion in 2028 at a compound annual growth rate (CAGR) of 7.8%. In the forecast period, growth can be attributed to several key factors. These include the increased utilization of telemedicine for pre and post-operative care in ASD cases, the growth of personalized treatment plans based on genetic and phenotypic data, the ongoing rise in global healthcare spending with a focus on emerging markets, the expanding elderly population leading to a higher incidence of congenital heart defects diagnosed later in life, international harmonization of medical device regulations enhancing global market access, and the implementation of national and international health programs targeting early detection and treatment of congenital heart diseases. Major trends expected in this period include the development of new, minimally invasive ASD closure devices, the integration of AI and machine learning for enhanced diagnosis and personalized treatment planning, the introduction of biodegradable and bioresorbable materials in device manufacturing, the utilization of AI-driven tools for real-time monitoring and decision support during ASD procedures, and the adoption of remote monitoring technologies for tracking patient recovery and early detection of complications.

The atrial septal defect market is anticipated to grow due to the rising prevalence of congenital heart defects (CHD). These defects are structural abnormalities in the heart that exist from birth. Treating atrial septal defects is crucial for managing CHD by correcting abnormal blood flow between the heart's chambers, improving heart function, and reducing associated complications. For example, data from the Australian Institute of Health and Welfare in June 2024 revealed that around 65,000 individuals in Australia, including children and adults, live with congenital heart disease. Hospitalizations related to congenital heart disease accounted for about 5,900 cases in the 2020-21 period, with 79 deaths occurring in infants under one year old, representing 7.8% of all infant deaths. This data underscores the driving force behind the atrial septal defect market's growth.

Key players in the arterial septal defect market are focusing on developing advanced devices and obtaining approvals to expand their availability and applications. Device approval is essential for gaining official authorization or certification from regulatory bodies before manufacturing, selling, or using a device in specific markets or purposes. For instance, in March 2024, Occlutech GmbH announced the FDA's approval of their Occlutech ASD Occluder and Occlutech Pistol Pusher for treating atrial septal defects (ASD). This milestone approval allows Occlutech to commercialize their devices in the US through an exclusive partnership with B. Braun Interventional Systems. The Occlutech ASD Occluder, a self-expanding nitinol device, offers a lifelong solution for patients with confirmed defects, enhancing healthcare globally.

In February 2022, Boston Scientific Corporation acquired Baylis Medical Company Inc. for $1.75 billion. This acquisition expands Boston Scientific's product portfolios in electrophysiology and structural heart interventions with Baylis Medical's transseptal platforms, guidewires, and left heart access tools, including the VersaCross RF Wire designed for creating atrial septal defects.

Major companies operating in the atrial septal defect market are Abbott Laboratories, Medtronic plc, Siemens Healthineers, Boston Scientific Corporation, Philips Healthcare, Edwards Lifesciences Corporation, W. L. Gore & Associates Inc., St. Jude Medical LLC, Cook Medical, Lepu Medical Technology Co. Ltd., MicroPort Scientific Corporation, Lifetech Scientific Corporation, Venus Medtech Hangzhou Inc, Occlutech Holding AG, Coherex Medical, Osypka AG, Arjo AB, Heart Medical Europe BV, AtriCure Inc., Asklepion Pharmaceuticals LLC.

North America was the largest region in the atrial septal defect market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the atrial septal defect market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the atrial septal defect market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The atrial septal defect (ASD) market consists of revenues earned by entities by provide services such as diagnosis and monitoring, medication management, and genetic counseling. The market value includes the value of related goods sold by the service provider or included within the service offering. The atrial septal defect (ASD) market also includes sales of septal occluder devices, cardiac MRI systems, and anticoagulant medications. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.